Bioglan will manufacture LECIGON® for Lobsor Pharmaceuticals

2 oktober, 2019


Bioglan will manufacture LECIGON® for Lobsor Pharmaceuticals

  • LECIGON® is a newly developed proprietary pharmaceutical treatment of advanced Parkinson’s disease
  • Bioglan will be the exclusive manufacturer for the European market


Malmö, Sweden, October 2nd, 2019, Bioglan, the Swedish subsidiary of the Spanish pharmaceutical company Reig Jofre, has now signed an agreement with Lobsor Pharmaceuticals for the exclusive manufacturing of LECIGON®, a medicine used for the treatment of advanced Parkinson’s disease.

Bioglan, a specialized pharmaceutical manufacturer and Lobsor Pharmaceuticals, specialty pharmaceutical company focused on innovative, proprietary technologies and drug formulations, for the treatment of Parkinson’s disease, announced the manufacturing collaboration of LECIGON®.

This agreement implies the expansion of Bioglan’s facilities, to meet the quality systems and the productive needs of Lobsor Pharmaceuticals. The investment dedicated to the installation of a fourth semi-solid production line amounts to 1 million euros.

Simon Björklund, CEO of Bioglan, commented: “LECIGON is a new and highly interesting drug which we believe will make a big difference for patients with advanced Parkinson´s disease. I am proud that Lobsor has decided to shift their manufacturing to Bioglan, who will be the exclusive manufacturer for the European market. A completely new production line will be dedicated to LECIGON with commercial manufacturing and supply starting in Q2 2020. Bioglan has since the 90s had three production lines for semi solid products and this addition of a fourth is in line with our company’s plan for further expansion. It is the trust, openness and good collaboration that brings Lobsor to Bioglan.

Ulf Rosen, CEO, Lobsor Pharmaceuticals commented: “We have had a very thorough procurement process and assessed several options regarding commercial scale manufacturing of LECIGON. As a company in early commercial stage, it is critical to choose the right partner, Bioglan ticks the boxes; large enough to provide highly scalable resources and with an entrepreneurial “can do” approach, a combination which is highly appreciated. We both share the ambition of growth and this collaboration will certainly provide mutual leverage.”


About Bioglan

Bioglan belongs to the Spanish pharmaceutical company Reig Jofre and is the center of excellence for semisolid product development and production. Bioglan offers both development and manufacturing services of pharmaceutical and medical devices. About 100 people work at Bioglan in the site in Malmö, Sweden. Reig Jofre focus its activity in research, development, manufacture and marketing of pharmaceutical products and nutritional supplements. Reig Jofre is publicly traded on the Spanish Stock Exchange. For more information,


About Lobsor

Lobsor Pharmaceuticals is a privately held company based in Uppsala, Sweden founded late 2013 by Ulf Rosén and Roger Bolsöy. It is a fully owned subsidiary to Lobsor Holding AB. The Lobsor team has substantial previous experience from the treatment of Parkinson’s disease in advanced stages especially continuous infusion of levodopa into the small intestine via a pump. Based on their experience, and close liaison with leading neurologists and patient organizations, the Lecigon treatment system has been developed with the aim of improving, in several aspects, daily living for individuals affected by progressive Parkinson’s disease and suitable for an invasive treatment. For more information, or


About Lecigon

LECIGON® is a patented pharmaceutical gel formulation containing a combination of levodopa/carbidopa and entacapone in a 50 ml pre-filled cartridge for continuous infusion into the small intestine. The treatment system also includes a newly developed wearable pump that weighs 134 grams. The product has obtained market authorization in Sweden and more countries are expected to follow during 2019.


For more information

Inma Santa-Pau – Head of Communication and Investor Relations

Tel. (+34) 935 450 078 –